- Home
- SPR vs GH Comparison
SPR vs GH Comparison
Compare SPR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPR
- GH
- Stock Information
- Founded
- SPR 1927
- GH 2011
- Country
- SPR United States
- GH United States
- Employees
- SPR N/A
- GH N/A
- Industry
- SPR Military/Government/Technical
- GH Medical Specialities
- Sector
- SPR Industrials
- GH Health Care
- Exchange
- SPR Nasdaq
- GH Nasdaq
- Market Cap
- SPR 4.3B
- GH 4.9B
- IPO Year
- SPR 2006
- GH 2018
- Fundamental
- Price
- SPR $40.08
- GH $50.15
- Analyst Decision
- SPR Hold
- GH Strong Buy
- Analyst Count
- SPR 4
- GH 20
- Target Price
- SPR $36.63
- GH $54.35
- AVG Volume (30 Days)
- SPR 1.3M
- GH 2.0M
- Earning Date
- SPR 08-04-2025
- GH 08-06-2025
- Dividend Yield
- SPR N/A
- GH N/A
- EPS Growth
- SPR N/A
- GH N/A
- EPS
- SPR N/A
- GH N/A
- Revenue
- SPR $6,135,600,000.00
- GH $773,996,000.00
- Revenue This Year
- SPR $25.26
- GH $23.14
- Revenue Next Year
- SPR $14.17
- GH $21.42
- P/E Ratio
- SPR N/A
- GH N/A
- Revenue Growth
- SPR N/A
- GH 28.20
- 52 Week Low
- SPR $27.00
- GH $20.14
- 52 Week High
- SPR $40.39
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- SPR 69.94
- GH 56.81
- Support Level
- SPR $38.41
- GH $48.90
- Resistance Level
- SPR $40.37
- GH $52.46
- Average True Range (ATR)
- SPR 0.74
- GH 1.97
- MACD
- SPR 0.21
- GH -0.23
- Stochastic Oscillator
- SPR 91.58
- GH 48.74
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing in mid-2025.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.